Business Context and Reporting Period
Company: Corvus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 6, 2020
Event: Announcement of new clinical and pre-clinical data for CPI-818 presented at the 62nd American Society of Hematology (ASH) Annual Meeting.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) focused on clinical trial updates and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The filing details significant clinical progress for CPI-818, an investigational ITK inhibitor, across two presentations:
Phase 1/1b Clinical Trial (T-Cell Lymphoma)
- Study Design: Adaptive, expansion cohort design evaluating safety, pharmacokinetics, and efficacy in patients with advanced, refractory T-cell lymphomas who failed multiple prior therapies.
- Enrollment: 25 patients enrolled (9 with Peripheral T-cell Lymphoma [PTCL], 12 with Cutaneous T-cell Lymphoma [CTCL], 4 with other T-cell lymphomas).
- PTCL Results (7 evaluable patients):
- Two objective tumor responses observed.
- One patient achieved a Complete Response (CR) at month 8, which persisted beyond 12 months of therapy and remained disease-free 14+ months after discontinuation.
- One patient achieved a Partial Response at four months.
- CTCL Results (11 evaluable patients):
- One patient achieved a Complete Response in lymph node disease with stable cutaneous disease at >12 months.
- Three patients achieved Stable Disease for 3 to 5 months.
- Safety and Pharmacokinetics: No dose-limiting toxicities or Grade 3/4 treatment-related adverse events observed. Dose-dependent receptor occupancy >75% observed at 200, 400, and 600 mg doses.
Pre-Clinical Data (Autoimmune Lymphoproliferative Syndrome - ALPS)
- Mechanism: CPI-818 inhibited activation of abnormal "double negative" T cells in ALPS patients in vitro.
- Animal Model: In MRL/lpr mice (model for ALPS), treatment reduced lymphadenopathy, splenomegaly, and autoimmune skin and kidney disease.
- Implication: Data supports evaluation of CPI-818 in ALPS patients.
Guidance, Outlook, and Risks
Outlook: The Company intends to advance CPI-818 based on the demonstrated safety and efficacy signals. The data supports further development in both oncology (T-cell lymphoma) and rare genetic diseases (ALPS).
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include:
- Ability to demonstrate sufficient evidence of efficacy and safety in ongoing and future clinical trials.
- Unpredictability of the regulatory process and FDA acceptance of data from foreign locations.
- Potential for clinical trial costs to exceed expectations.
- Ability to raise additional capital.
- Impact of the COVID-19 pandemic on clinical programs and operations.
Investor Verification Checklist
- Verify the full text of Abstract #2068 and Abstract #95 on the Corvus Pharmaceuticals website or ASH archives.
- Review the Company's most recent Form 10-Q (filed October 29, 2020) for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Monitor upcoming regulatory filings for the initiation of Phase 2 trials or new INDs for ALPS.
- Assess the durability of the Complete Response in the PTCL patient who has been off therapy for 14+ months.